Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE

Advances in Therapy

Volumn 26, Issue 5, 2009, Pages 535-551

  Fontaine, Pierre ^a   Gin, Henri ^b   Pinget, Michel ^c   Thivolet, Charles ^d   Hanaire, Hélène ^e   Robert, Jean Jacques ^f   Marre, Michel ^g   Venkatanarasimhachar, Srishyla ^h  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Unit of Standard Care   (France)

^c HÔPITAL CIVIL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CHU RANGUEIL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g BICHAT HOSPITAL   (France)

^h NOVO NORDISK A S   (Denmark)

Author keywords

Detemir; Insulin analog; Once daily; PREDICTIVE; Twice daily; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 73449139073     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0033-6     Document Type: Article

References (18)

1. S. Havelund A. Plum U. Ribel 2004 The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin Pharm Res 21 1498 1504 15359587 10.1023/B:PHAM.0000036926.54824.37 1:CAS:528:DC%2BD2cXmtlGntbg%3D (Pubitemid 39149667)
2. J. Plank M. Bodenlenz F. Sinner 2005 A double-blind, randomised, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 28 1107 1112 15855574 10.2337/diacare.28.5.1107 1:CAS:528:DC%2BD2MXksF2hu7k%3D (Pubitemid 40616620)
3. T. Heise L. Nosek B.B. Rønn 2004 Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 53 1614 1620 15161770 10.2337/diabetes.53.6.1614 1:CAS:528:DC%2BD2cXkslCgsLc%3D (Pubitemid 38697678)
4. A. Wutte J. Plank M. Bodenlenz 2007 Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus Exp Clin Endocrinol Diabetes 115 461 467 17647145 10.1055/s-2007-976512 1:CAS:528:DC%2BD2sXps1aktL0%3D (Pubitemid 47234648)
5. O. Klein J. Lynge L. Endahl 2007 Albumin-bound basal insulin analogs (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 9 290 299 17391154 10.1111/j.1463-1326.2006.00685.x 1:CAS:528:DC%2BD2sXlvVSlu7c%3D (Pubitemid 46502046)
6. P. Home P. Kurtzhals 2006 Insulin detemir: from concept to clinical experience Expert Opin Pharmacother 7 325 343 16448327 10.1517/14656566.7.3.325 1:CAS:528:DC%2BD28XpsVaruw%3D%3D (Pubitemid 43263250)
7. P.C. Bartley M. Bogoev J. Larsen 2008 Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basalbolus regimen with insulin aspart at meals: a 2-year, randomised, controlled trial Diabet Med 25 442 449 18387078 10.1111/j.1464-5491.2007.02407.x 1:CAS:528:DC%2BD1cXmsFKgtr4%3D
8. T. Heise T.R. Pieber 2007 Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogs based on isoglycemic clamp studies Diabetes Obes Metab 9 648 659 17645556 10.1111/j.1463-1326.2007.00756.x 1:CAS:528:DC%2BD2sXhtFGgt7rP (Pubitemid 47261846)
9. A. Philis-Tsimikas G. Charpentier P. Clauson 2006 Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 28 1569 1581 17157113 10.1016/j.clinthera.2006.10.020 1:CAS:528:DC%2BD28XhtlartrzF (Pubitemid 44856694)
10. J.-P. Le Floch M. Lévy H. Mosnier-Pudar 2009 Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT) Diabetes Care 32 32 37 18945928 10.2337/dc08-0332
11. A. Dornhorst H.J. Lüddeke S. Sreenan 2007 Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort Int J Clin Pract 61 523 528 17313628 10.1111/j.1742-1241.2007.01316.x 1:CAS:528:DC%2BD2sXmtFKhtrk%3D (Pubitemid 46271267)
12. J.H. De Vries M. Nattrass T.R. Pieber 2007 Refining basal insulin therapy: what have we learned in the age of analogs? Diabetes Metab Res Rev 23 441 454 10.1002/dmrr.762 (Pubitemid 47526934)
13. H.J. Lüddeke S. Sreenan S. Aczel 2007 PREDICTIVE Study Group. PREDICTIVE - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort Diabetes Obes Metab 9 428 434 17391171 10.1111/j.1463-1326.2006.00677.x (Pubitemid 46502063)
14. L.F. Meneghini K.H. Rosenberg C. Koenen 2007 Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study Diabetes Obes Metab 9 418 427 17391170 10.1111/j.1463-1326.2006.00674.x 1:CAS:528:DC%2BD2sXlvVSks74%3D (Pubitemid 46502062)
15. A. Dornhorst H.J. Lüddeke C. Koenen 2008 Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basalonly therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE Diabetes Obes Metab 10 75 81 18034846 1:CAS:528:DC%2BD1cXislCrsrk%3D
16. A. Dornhorst H.J. Lüddeke S. Sreenan 2008 Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study Int J Clin Pract 62 659 665 18324957 10.1111/j.1742-1241.2008.01715.x 1:STN:280:DC%2BD1c3jvFGjtw%3D%3D (Pubitemid 351348041)
17. M. Honka 2008 Results of the PREDICTIVE project in the Czech Republic [in Czech] Vnitr Lek 54 361 367 18630615 1:STN:280:DC%2BD1cvlsFyktA%3D%3D
18. R.R. Holman K.I. Thorne A.J. Farmer 2007 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes N Engl J Med 357 1716 1730 17890232 10.1056/NEJMoa075392 1:CAS:528:DC%2BD2sXht1alsLjM (Pubitemid 350005153)